Roles of human urotensin-ii, creatine kinase-mb, and uric acid serum levels in hypertrophic cardiomyopathy patients

Background: Hypertrophic cardiomyopathy (HCM) is a genetic condition with the hallmark feature of left ventricular hypertrophy. Human UT-II is regarded as a cardiovascular autacoid/hormone, and its roles in cardiac inotropic and hypertrophic properties. Objective: Aims of this study were to elucidate the clinical significance of serum hUT-II levels as a potential new biomarker in patients with HCM and also to evaluate Serum levels CK-MB and UA in HCM. Patients and Methods: This study included 40 HCM patients (60% males and 40% females) and were compared to 30 healthy control subjects (47% males and 53% females. All patients underwent extensive clinical, laboratory, and echocardiographic. Blood samples were taken to test for serum hUT-II levels by commercial ELISA Kit and Serum CK-MB, UA levels were measured by a photometric enzymatic method. Results: Serum hUT-II was significantly higher (p<0.01) in patients with HCM (15.8±2.1 pmol/L) compared with healthy controls (3.3±1.7 pmol/L). With regard to HCM patient, Serum hUT-II levels were significantly higher in the female with (16.3±1.9 pmol/L) than the male with (15.4±2.2 pmol/L) (p<0.05). Besides, abnormal elevation of serum CK-MB was observed in the HCM patients (39.7±8.0 U/L). Serum UA was significantly elevated in HCM patients (7.7±0.7 mg/dL) than in the control group (3.7±0.6 mg/dL) (p<0.01). Among echocardiographic parameters, hUT-II was negatively associated with ejection fraction (r = -0.160, p=0.324). Conclusion: Results of the first study indicated that serum hUT-II levels were markedly elevated in patients with HCM. Serum hUT-II is a novel biomarker parameter that has clinical use in patients with the severity of LVH. Elevation of serum CK-MB cardiac enzyme in HCM patients indicated to ongoing myocardial injury. In addition, SUA values are significantly increased and independently related with HCM patients.